140 related articles for article (PubMed ID: 23666171)
1. Diagnostic power of 24S-hydroxycholesterol in cerebrospinal fluid: candidate marker of brain health.
Leoni V; Solomon A; Lövgren-Sandblom A; Minthon L; Blennow K; Hansson O; Wahlund LO; Kivipelto M; Björkhem I
J Alzheimers Dis; 2013; 36(4):739-47. PubMed ID: 23666171
[TBL] [Abstract][Full Text] [Related]
2. Are the CSF levels of 24S-hydroxycholesterol a sensitive biomarker for mild cognitive impairment?
Leoni V; Shafaati M; Salomon A; Kivipelto M; Björkhem I; Wahlund LO
Neurosci Lett; 2006 Apr 10-17; 397(1-2):83-7. PubMed ID: 16406316
[TBL] [Abstract][Full Text] [Related]
3. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.
Buchhave P; Minthon L; Zetterberg H; Wallin AK; Blennow K; Hansson O
Arch Gen Psychiatry; 2012 Jan; 69(1):98-106. PubMed ID: 22213792
[TBL] [Abstract][Full Text] [Related]
4. Cholesterol, 24-Hydroxycholesterol, and 27-Hydroxycholesterol as Surrogate Biomarkers in Cerebrospinal Fluid in Mild Cognitive Impairment and Alzheimer's Disease: A Meta-Analysis.
Wang HL; Wang YY; Liu XG; Kuo SH; Liu N; Song QY; Wang MW
J Alzheimers Dis; 2016; 51(1):45-55. PubMed ID: 26836015
[TBL] [Abstract][Full Text] [Related]
5. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD
J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385
[TBL] [Abstract][Full Text] [Related]
6. Plasma levels of 24S-hydroxycholesterol reflect brain volumes in patients without objective cognitive impairment but not in those with Alzheimer's disease.
Solomon A; Leoni V; Kivipelto M; Besga A; Oksengård AR; Julin P; Svensson L; Wahlund LO; Andreasen N; Winblad B; Soininen H; Björkhem I
Neurosci Lett; 2009 Oct; 462(1):89-93. PubMed ID: 19560513
[TBL] [Abstract][Full Text] [Related]
7. Performance of aβ1-40, aβ1-42, total tau, and phosphorylated tau as predictors of dementia in a cohort of patients with mild cognitive impairment.
Parnetti L; Chiasserini D; Eusebi P; Giannandrea D; Bellomo G; De Carlo C; Padiglioni C; Mastrocola S; Lisetti V; Calabresi P
J Alzheimers Dis; 2012; 29(1):229-38. PubMed ID: 22232006
[TBL] [Abstract][Full Text] [Related]
8. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.
Mattsson N; Zetterberg H; Hansson O; Andreasen N; Parnetti L; Jonsson M; Herukka SK; van der Flier WM; Blankenstein MA; Ewers M; Rich K; Kaiser E; Verbeek M; Tsolaki M; Mulugeta E; Rosén E; Aarsland D; Visser PJ; Schröder J; Marcusson J; de Leon M; Hampel H; Scheltens P; Pirttilä T; Wallin A; Jönhagen ME; Minthon L; Winblad B; Blennow K
JAMA; 2009 Jul; 302(4):385-93. PubMed ID: 19622817
[TBL] [Abstract][Full Text] [Related]
9. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
[TBL] [Abstract][Full Text] [Related]
10. Cerebrospinal fluid Aβ42 is the best predictor of clinical progression in patients with subjective complaints.
van Harten AC; Visser PJ; Pijnenburg YA; Teunissen CE; Blankenstein MA; Scheltens P; van der Flier WM
Alzheimers Dement; 2013 Sep; 9(5):481-7. PubMed ID: 23232269
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal cerebrospinal fluid biomarkers over four years in mild cognitive impairment.
Mattsson N; Portelius E; Rolstad S; Gustavsson M; Andreasson U; Stridsberg M; Wallin A; Blennow K; Zetterberg H
J Alzheimers Dis; 2012; 30(4):767-78. PubMed ID: 22475796
[TBL] [Abstract][Full Text] [Related]
12. Cerebrospinal fluid cortisol and clinical disease progression in MCI and dementia of Alzheimer's type.
Popp J; Wolfsgruber S; Heuser I; Peters O; Hüll M; Schröder J; Möller HJ; Lewczuk P; Schneider A; Jahn H; Luckhaus C; Perneczky R; Frölich L; Wagner M; Maier W; Wiltfang J; Kornhuber J; Jessen F
Neurobiol Aging; 2015 Feb; 36(2):601-7. PubMed ID: 25435336
[TBL] [Abstract][Full Text] [Related]
13. Potential diagnostic applications of side chain oxysterols analysis in plasma and cerebrospinal fluid.
Leoni V; Caccia C
Biochem Pharmacol; 2013 Jul; 86(1):26-36. PubMed ID: 23541982
[TBL] [Abstract][Full Text] [Related]
14. The association between biomarkers in cerebrospinal fluid and structural changes in the brain in patients with Alzheimer's disease.
Li X; Li TQ; Andreasen N; Wiberg MK; Westman E; Wahlund LO
J Intern Med; 2014 Apr; 275(4):418-27. PubMed ID: 24237038
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of visinin-like protein 1 concentrations in the cerebrospinal fluid of patients with mild cognitive impairment as a dynamic biomarker of Alzheimer's disease.
Mroczko B; Groblewska M; Zboch M; Muszyński P; Zajkowska A; Borawska R; Szmitkowski M; Kornhuber J; Lewczuk P
J Alzheimers Dis; 2015; 43(3):1031-7. PubMed ID: 25159667
[TBL] [Abstract][Full Text] [Related]
16. Varying strength of cognitive markers and biomarkers to predict conversion and cognitive decline in an early-stage-enriched mild cognitive impairment sample.
Egli SC; Hirni DI; Taylor KI; Berres M; Regeniter A; Gass A; Monsch AU; Sollberger M
J Alzheimers Dis; 2015; 44(2):625-33. PubMed ID: 25322924
[TBL] [Abstract][Full Text] [Related]
17. Glycan biomarkers for Alzheimer disease correlate with T-tau and P-tau in cerebrospinal fluid in subjective cognitive impairment.
Schedin-Weiss S; Gaunitz S; Sui P; Chen Q; Haslam SM; Blennow K; Winblad B; Dell A; Tjernberg LO
FEBS J; 2020 Aug; 287(15):3221-3234. PubMed ID: 31889402
[TBL] [Abstract][Full Text] [Related]
18. Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer's disease in a memory clinic cohort.
Kester MI; Teunissen CE; Sutphen C; Herries EM; Ladenson JH; Xiong C; Scheltens P; van der Flier WM; Morris JC; Holtzman DM; Fagan AM
Alzheimers Res Ther; 2015 Sep; 7(1):59. PubMed ID: 26383836
[TBL] [Abstract][Full Text] [Related]
19. Association of pituitary adenylate cyclase-activating polypeptide with cognitive decline in mild cognitive impairment due to Alzheimer disease.
Han P; Caselli RJ; Baxter L; Serrano G; Yin J; Beach TG; Reiman EM; Shi J
JAMA Neurol; 2015 Mar; 72(3):333-9. PubMed ID: 25599520
[TBL] [Abstract][Full Text] [Related]
20. Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI.
Vos SJ; van Rossum IA; Verhey F; Knol DL; Soininen H; Wahlund LO; Hampel H; Tsolaki M; Minthon L; Frisoni GB; Froelich L; Nobili F; van der Flier W; Blennow K; Wolz R; Scheltens P; Visser PJ
Neurology; 2013 Mar; 80(12):1124-32. PubMed ID: 23446677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
